GSK Spotlights Three Impending Drug Launches In 3Q Update
Executive Summary
GlaxoSmithKline focused on three upcoming launches for its pharmaceutical business during its Q3 update, during which CEO Emma Walmsley also speculated briefly about acquiring Pfizer's consumer health business.
You may also be interested in...
GSK Bags Barron As R&D Boss As Vallance Joins UK Government
UK pharma giant GlaxoSmithKline has nabbed a high-profile figure from Google's Calico to head up its research efforts. Barron's oncology pedigree from his time at Roche suggests that cancer is again a core area for GSK.
Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
As Pfizer re-examines a potential sale of its consumer business, analysts expect it would attract suitors with a likely price of $15bn to $17bn, but also say it might be better off continuing to compete in the sector that accounted for around $3.4bn of its 2016 revenues.
Trelegy Approval Boosts GSK's US Respiratory Business But Pressure Remains
With the FDA approval of Trelegy Ellipta, GlaxoSmithKline will enjoy first-to-market status with a LABA/LAMA/ICS triple combination therapy to treat COPD in the US. However, it faces the challenge of convincing payers.